Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08).

Détails

ID Serval
serval:BIB_6DA91E6BDAAE
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08).
Périodique
British journal of cancer
Auteur(s)
Curioni-Fontecedro A., Perentes J.Y., Gelpke H., Xyrafas A., Bouchaab H., Mach N., Matzinger O., Stojcheva N., Frueh M., Weder W., Cathomas R., Gargiulo P., Bubendorf L., Pless M., Betticher D., Peters S.
Collaborateur(s)
Swiss Group of Clinical Cancer Research (SAKK)
ISSN
1532-1827 (Electronic)
ISSN-L
0007-0920
Statut éditorial
Publié
Date de publication
05/2019
Peer-reviewed
Oui
Volume
120
Numéro
10
Pages
968-974
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Neoadjuvant chemotherapy (CT) followed by radiotherapy (RT) and surgery showed a median survival of 28.7 months in resectable stage IIIB non-small-cell lung cancer (NSCLC) patients (pts). Here, we evaluate the impact of concomitant cetuximab to the same neoadjuvant chemo-radiotherapy (CRT) in selected patients (pts) with NSCLC, stage IIIB.
Resectable stage IIIB NSCLC received three cycles of CT (cisplatin 100 mg/m <sup>2</sup> and docetaxel 85 mg/m <sup>2</sup> d1, q3w) followed by RT (44 Gy in 22 fractions) with concomitant cetuximab (250 mg/m <sup>2</sup> , q1w) and subsequent surgery. The primary endpoint was 1-year progression-free survival (PFS).
Sixty-nine pts were included in the trial. Fifty-seven (83%) pts underwent surgery, with complete resection (R0) in 42 (74%) and postoperative 30 day mortality of 3.5%. Responses were: 57% after CT-cetuximab and 64% after CRT-cetuximab. One-year PFS was 50%. Median PFS was 12.0 months (95% CI: 9.0-15.6), median OS was 21.3 months, with a 2- and 3-yr survival of 41% and 30%, respectively.
This is one of the largest prospective phase 2 trial to investigate the role of induction CRT and surgery in resectable stage IIIB disease, and the first adding cetuximab to the neoadjuvant strategy. This trial treatment is feasible with promising response and OS rates, supporting an aggressive approach in selected pts.
Pubmed
Web of science
Open Access
Oui
Création de la notice
28/04/2019 14:42
Dernière modification de la notice
20/08/2019 14:27
Données d'usage